论文部分内容阅读
目的:探讨匹多莫德在小儿反复呼吸道感染(RRI)中的治疗效果。方法:将确诊的RRI 56例患儿随机分为治疗组34例和对照组22例,对照组给予一般常规治疗,不加用任何免疫调节剂;治疗组在常规治疗基础上给予匹多莫德颗粒口服,<2岁每次200 mg,每日2次,两周后改为每日1次,每次200 mg,连服6周;>2岁每次400 mg,每日2次,两周后改为每日1次,每次400 mg,连服6周,均用1个疗程两个月。于治疗前1天及治疗1个疗程后分别测定T细胞亚群及Ig A、Ig G、Ig M,观察两组患儿的治疗效果及不良反应。结果:治疗组有效率明显高于对照组,差异有统计学意义(P<0.05);治疗组治疗前、后CD3、CD4及Ig A、Ig G比较差异有统计学意义(P<0.05)。结论:匹多莫德在小儿RRI治疗中疗效显著,同时能够明显提高RRI患儿细胞免疫及体液免疫功能,值得临床推广。
Objective: To investigate the therapeutic effect of pidotimod in children with recurrent respiratory tract infections (RRI). Methods: Fifty-six children diagnosed with RRI were randomly divided into treatment group (n = 34) and control group (n = 22). The control group was given conventional treatment without any immunomodulatory agent. The treatment group was given Pidotimod Oral particles, <2 years old each 200 mg, 2 times a day, two weeks later changed to daily 200 mg, and even served 6 weeks;> 2 years old each 400 mg, 2 times a day, two Weekly changed to 1 day, 400 mg each, and even served 6 weeks, both with a course of two months. One day before treatment and one course of treatment, the T cell subsets and Ig A, Ig G and Ig M were measured respectively. The therapeutic effects and adverse reactions in both groups were observed. Results: The effective rate of the treatment group was significantly higher than that of the control group (P <0.05). There was significant difference in the CD3, CD4, IgA and Ig G before and after treatment in the treatment group (P <0.05). Conclusion: Pidotimod is effective in pediatric RRI treatment and can significantly improve the cellular immunity and humoral immune function in children with RRI, which is worthy of clinical promotion.